“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...

-Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study ...

Vertex Pharmaceuticals today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery. -VX-150 was generally well ...

This Phase 2 study is the second positive proof-of-concept study for VX-150 and provides further validation for the use of a NaV1.8 inhibitor for the treatment of pain. A third Phase 2 study of VX-150 ...

Vertex Pharmaceuticals Incorporated VRTX announced positive results from a phase II study evaluating its NaV1.8 inhibitor VX-150 in patients suffering from pain caused by small fiber neuropathy. The ...

Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated. -Treatment with the NaV1.8 inhibitor VX-150 ...

Following the positive Phase II results earlier this year and having reached agreement on the design of the pivotal development program with the US Food and Drug Administration (FDA), Vertex ...

BOSTON, August 04, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, ...

Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Q3 financials are strong: 6% revenue growth, 87.16% gross profit margin, driven by ...